Pharma & Life Sciences

Method and System for Fully Continuous-Flow Preparation of Nitroimidazole Antimicrobial Agent

USPTO published patent application US20260098016A1 for a fully continuous-flow method of synthesizing nitroimidazole antimicrobial agents. The method uses glyoxal aqueous solution, acetaldehyde aqueous solution, and ammonium hydroxide as raw materials through multi-step chemical reactions. Inventors include Fener Chen, Minjie Liu, Li Wan, Yajiao Zhang, Xingpeng Cai, and Zhisheng Yang. The system includes micromixers, microreactors, back pressure valves, gas-liquid separators, and online solvent switching units.

Novel Aromatic Ring Derivative Containing Amide Substitution as TYK2 Inhibitor

The USPTO has published patent application US20260098017A1 for a novel aromatic ring derivative containing amide substitution as a TYK2 inhibitor for treating inflammatory and autoimmune diseases including psoriasis, psoriatic arthritis, dermatitis, lupus, inflammatory bowel disease, and rheumatoid arthritis. The application was filed December 22, 2023, with inventors including Wenzhi Wang, Shuangyong Sun, and colleagues. The invention demonstrates therapeutic efficacy in psoriasis and asthma animal models with good druggability, stability, and safety profiles.

Bicyclic 1,4-Diazepanones and Therapeutic Uses

The USPTO published patent application US20260098018A1 disclosing bicyclic 1,4-diazepanone compounds of formula (I) and their therapeutic uses for treating diseases responsive to modulation of skeletal sarcomere contractility. The application names 15 inventors and was filed July 7, 2025 under Application No. 19261878.

NSAID Conjugate Anti-Inflammatory Compounds Via Microwave Synthesis

The USPTO published patent application US20260098019A1 for microwave-synthesized NSAID conjugate compounds containing triazolyl heterocycles. The compounds are derivatives of FDA-approved anti-inflammatory drugs such as ibuprofen and indomethacin. The application claims improved anti-inflammatory efficacy with reduced ulcerogenic effects and selective COX-2 inhibition over COX-1.

Ultra-Long-Acting Platform Comprising Fc-Advanced Fatty Acid Chain Extending Drug Half-Life

The USPTO published patent application US20260097125A1 for an ultra-long-acting drug delivery platform combining immunoglobulin Fc with a modified C14-24 fatty acid chain. The conjugated molecule structure 'active molecule-Fc-Cn' is designed to extend the half-life of therapeutic active molecules. The application was filed on September 22, 2023, with eight inventors including Faming Zhang, Yimin Hu, and colleagues.

Blaine Labs Recalls Revitaderm and Tridergel Wound Care Gel Due to Microbial Contamination

Blaine Labs, Inc. has voluntarily recalled three lot numbers of Revitaderm and Tridergel Wound Care Gel products (BL3608, BL3435, BL3525) distributed nationwide to healthcare providers due to contamination with Lysinibacillus fusiformis, an environmental spore-forming bacterium. The contaminated 1 oz. and 3 oz. antiseptic wound gels pose infection risk to patients with open wounds, compromised skin barriers, or weakened immune systems.

Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion

Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion

Universal Peptide/MHC Complexes with Engineered Disulfide

The USPTO published patent application US20260097105A1 by Nikolaos SGOURAKIS for synthetic major histocompatibility complex (MHC) molecules featuring engineered disulfide linkages connecting heavy and light chains. The invention covers systems, formulations, and methods for generating universal peptide/MHC complexes using structure-guided modeling and design. Application No. 19114130 was filed September 28, 2023, with CPC classifications including A61K 39/001188, A61K 39/385, C07K 14/4748, and C07K 14/70539.

Flavivirus Vaccine Polynucleotides Inducing Protective CD8+ T Cell Immunity

USPTO published patent application US20260097108A1 by inventors Charneau et al. disclosing recombinant polynucleotides encoding non-structural antigens from Dengue virus (DENV), Zika virus (ZIKV), and Yellow Fever virus (YFV) designed to elicit protective CD8+ T-cell immune responses. The application covers polyepitope fusion polypeptides and lentiviral vectors for flavivirus vaccine development.

Erythroid Lineages from Pluripotent Cells

USPTO published patent application US20260097074A1 by Dhvanit Shah disclosing methods for generating hematopoietic lineages including erythroid progenitor cells, progenitor erythroblasts, and erythroid cells from human induced pluripotent stem cells (iPSCs) for cell therapy applications. The application covers efficient ex vivo processes for developing these lineages and isolated cell compositions produced by the methods.